Economic evaluation of NT-proBNP for heart failure risk assessment in patients with type 2 diabetes in China
Authors' conclusion
NT-proBNP is a dominant and robust cost-saving strategy for HF risk assessment in patients with T2DM in China, reducing both HF cases and associated healthcare costs.
Study context
- Population
- Simulated patients with T2D aged ≥40 years in China; high-risk patients received SGLT2 inhibitors plus standard of care
- Comparison
- NT-proBNP-guided heart failure (HF) risk assessment vs usual care vs Systematic COronary Risk Evaluation (SCORE)
- Outcome
- Cost-effectiveness: lifetime direct medical costs (US$) and QALYs
- Follow-up
- Lifetime
Methodological detailscost-effectiveness analysis, decision tree and Markov model, 1-year cycles, lifetime horizon, Chinese healthcare perspective, probabilistic sensitivity analysis
- Cost-effectiveness analysis
- Decision tree and Markov model
- 1-year cycles
- Lifetime horizon
- Chinese healthcare perspective
- Probabilistic sensitivity analysis
Main finding
As reported in the abstract
Cost difference
1002.73 US$
lower costs with NT-proBNP-guided
QALY gain
0.055 QALYs per patient
higher with NT-proBNP-guided
Further findings
Probabilistic sensitivity analysis
- Probability of NT-proBNP strategy being cost-saving vs usual care
- 96.9 %
Original publication
Economic evaluation of NT-proBNP for heart failure risk assessment in patients with type 2 diabetes in China. Diabetes Res Clin Pract. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →